The present invention relates to the field of liver diseases, more particularly to the field of portal hypertension and liver cirrhosis. The invention relates to the use of molecules which can inhibit the binding of placental growth factor (PIGF) to its receptor (VEGFR-1), such as monoclonal antibodies, for the manufacture of a medicament to treat liver cirrhosis, portal hypertension and its complications.